The safety of JAK kinase inhibitors for the treatment of myelofibrosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The safety of JAK kinase inhibitors for the treatment of myelofibrosis
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages 1-16
Publisher
Informa UK Limited
Online
2020-12-18
DOI
10.1080/14740338.2021.1865912
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
- (2020) Claire N. Harrison et al. AMERICAN JOURNAL OF HEMATOLOGY
- MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis
- (2020) John Mascarenhas et al. BLOOD
- Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
- (2020) Claire N Harrison et al. BLOOD
- A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
- (2020) Aaron T. Gerds et al. BLOOD
- Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
- (2020) Haifa Kathrin Al‐Ali et al. BRITISH JOURNAL OF HAEMATOLOGY
- Fedratinib in myelofibrosis
- (2020) Ann Mullally et al. Blood Advances
- A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis
- (2019) Prithviraj Bose et al. LEUKEMIA & LYMPHOMA
- Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis
- (2019) Rachel B. Salit et al. BONE MARROW TRANSPLANTATION
- Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
- (2019) Barbara Mora et al. Cancer Medicine
- Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.
- (2019) Anders Lindholm Sørensen et al. HAEMATOLOGICA
- Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation
- (2018) Nicolaus Kröger et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development
- (2018) Jim Zheng et al. DRUG METABOLISM AND DISPOSITION
- Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis
- (2018) Sharifah Shahnaz Syed Abd Kadir et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
- (2018) Nicola Polverelli et al. HEMATOLOGICAL ONCOLOGY
- Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms
- (2018) J. Berdeja et al. LEUKEMIA RESEARCH
- Momelotinib therapy for myelofibrosis: a 7-year follow-up
- (2018) Ayalew Tefferi et al. Blood Cancer Journal
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- Ruxolitinib Therapy Followed by Reduced Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis – Myeloproliferative Disorders Research Consortium 114 study
- (2018) Vikas Gupta et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis
- (2018) Lucia Masarova et al. BLOOD
- A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
- (2018) Stephen Couban et al. Journal of Hematology & Oncology
- EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis
- (2018) Alessandro M. Vannucchi et al. HAEMATOLOGICA
- Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
- (2017) Francesca Palandri et al. HEMATOLOGICAL ONCOLOGY
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
- (2017) A Pardanani et al. LEUKEMIA
- Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition
- (2017) E Leroy et al. LEUKEMIA
- Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
- (2017) K. Gowin et al. LEUKEMIA RESEARCH
- Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke’s encephalopathy
- (2017) Alan S. Hazell et al. NEUROSCIENCE LETTERS
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
- (2016) Nicola Polverelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
- (2016) Mohamed Shanavas et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms
- (2016) A Hanif et al. BONE MARROW TRANSPLANTATION
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- (2016) Srdan Verstovsek et al. Journal of Hematology & Oncology
- A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
- (2016) S Verstovsek et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Molecular insights into regulation of JAK2 in myeloproliferative neoplasms
- (2015) O. Silvennoinen et al. BLOOD
- Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis
- (2015) Greg L. Plosker DRUGS
- A comprehensive review of pacritinib in myelofibrosis
- (2015) Srdan Verstovsek et al. Future Oncology
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Phase I dose escalation study of lestaurtinib in patients with myelofibrosis
- (2015) Elizabeth O. Hexner et al. LEUKEMIA & LYMPHOMA
- Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera – single center experience
- (2015) Lucia Masarova et al. LEUKEMIA & LYMPHOMA
- A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis
- (2015) Srdan Verstovsek et al. LEUKEMIA RESEARCH
- Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome
- (2015) Lucia Masarova et al. LEUKEMIA RESEARCH
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
- (2014) Ramy A. Abdelrahman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
- (2014) Yan Beauverd et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
- (2014) T Stübig et al. LEUKEMIA
- Disseminated tuberculosis associated with ruxolitinib
- (2014) R K Hopman et al. LEUKEMIA
- Glutathione S-Transferase T1 and M1 Polymorphisms Are Associated with Lung Cancer Risk in a Gender-Specific Manner
- (2014) Chunguo Pan et al. Oncology Research and Treatment
- Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
- (2013) N Jaekel et al. BONE MARROW TRANSPLANTATION
- Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis
- (2013) Tong Dai et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
- (2013) Moshe Talpaz et al. Journal of Hematology & Oncology
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
- (2013) T Zhou et al. LEUKEMIA
- Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
- (2013) M Massa et al. LEUKEMIA
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
- (2013) Srdan Verstovsek et al. LEUKEMIA RESEARCH
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition
- (2012) Sonam Prakash et al. MODERN PATHOLOGY
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age
- (2011) Scott Samuelson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
- (2011) O Abdel-Wahab et al. LEUKEMIA
- SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
- (2011) S Hart et al. LEUKEMIA
- Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients
- (2010) E. Rumi et al. HAEMATOLOGICA
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
- (2010) A Pardanani et al. LEUKEMIA
- Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
- (2009) A. M. Vannucchi et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
- (2009) Ruben A. Mesa et al. LEUKEMIA RESEARCH
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started